ESMO Media Releases

A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America. The scale, called ESCAT (ESMO Scale for Clinical Actionability of molecular Targets), is published this week in the Annals of Oncology.

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO), the world’s two leading organisations for oncology professionals, today issued a joint statement calling upon governments to renew political commitment to improve cancer services and reduce cancer deaths.

The Molecular Analysis for Personalised therapy (MAP) Congress is a one-of-a-kind meeting designed to answer the critical question about how to integrate in daily practice the wealth of information coming from the analysis of tumour samples.

ESMO 20^th World Congress on Gastrointestinal Cancer celebrates two decades of clinical progress and examines further promising research

ESMO, the leading European professional organisation for medical oncology, has announced that the ESMO 2020 Annual Congress will take place from 18 to 22 September 2020, at the IFEMA – Feria de Madrid, Spain.

Researchers have shown for the first time that a form of artificial intelligence or machine learning known as a deep learning convolutional neural network (CNN) is better than experienced dermatologists at detecting skin cancer.

Nearly 25,000 participants from all over the world are expected in Munich, Germany, between 19-23 October to attend the leading international oncology event in Europe, the ESMO 2018 Congress

At the 71st World Health Assembly (WHA) in Geneva, Switzerland, ESMO, the leading professional organisation for medical oncology, delivered two statements positioning cancer as a priority on the World Health Organisation’s (WHO) global agenda.

ESMO, the leading professional organisation for medical oncology, shares concerns expressed in a scientific paper and reflected in the international media about the rising costs of cancer medicines.

Investing in the continuity of care for lung cancer patients can bring tremendous benefits in terms of patient satisfaction and quality of life.

Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial presented at the ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.